Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI 48109, USA.
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Cells. 2021 Sep 14;10(9):2415. doi: 10.3390/cells10092415.
Cancer has long been viewed as a disease of normal development gone awry. Cancer stem-like cells (CSCs), also termed as tumor-initiating cells (TICs), are increasingly recognized as a critical tumor cell population that drives not only tumorigenesis but also cancer progression, treatment resistance and metastatic relapse. The let-7 family of microRNAs (miRNAs), first identified in C. elegans but functionally conserved from worms to human, constitutes an important class of regulators for diverse cellular functions ranging from cell proliferation, differentiation and pluripotency to cancer development and progression. Here, we review the current state of knowledge regarding the roles of let-7 miRNAs in regulating cancer stemness. We outline several key RNA-binding proteins, long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) involved in the regulation of let-7 biogenesis, maturation and function. We then highlight key gene targets and signaling pathways that are regulated or mutually regulated by the let-7 family of miRNAs to modulate CSC characteristics in various types of cancer. We also summarize the existing evidence indicating distinct metabolic pathways regulated by the let-7 miRNAs to impact CSC self-renewal, differentiation and treatment resistance. Lastly, we review current preclinical studies and discuss the clinical implications for developing let-7-based replacement strategies as potential cancer therapeutics that can be delivered through different platforms to target CSCs and reduce/overcome treatment resistance when applied alone or in combination with current chemo/radiation or molecularly targeted therapies. By specifically targeting CSCs, these strategies have the potential to significantly improve the efficacy of cancer therapies.
癌症长期以来被视为一种异常的正常发育疾病。癌症干细胞样细胞(CSCs),也称为肿瘤起始细胞(TICs),越来越被认为是一种关键的肿瘤细胞群体,不仅驱动肿瘤发生,而且还驱动肿瘤进展、治疗耐药和转移复发。微 RNA(miRNA)家族 let-7,最初在秀丽隐杆线虫中被鉴定,但从线虫到人功能保守,构成了调节从细胞增殖、分化和多能性到癌症发生和进展等多种细胞功能的重要一类调节剂。在这里,我们回顾了 let-7 miRNA 调节癌症干性的最新知识状态。我们概述了几个关键的 RNA 结合蛋白、长非编码 RNA(lncRNA)和环状 RNA(circRNA),它们参与 let-7 生物发生、成熟和功能的调节。然后,我们重点介绍了关键的基因靶标和信号通路,这些靶标和信号通路受 let-7 家族 miRNA 的调节,以调节各种类型癌症中的 CSC 特征。我们还总结了目前的证据,表明 let-7 miRNA 调节的不同代谢途径可影响 CSC 的自我更新、分化和治疗耐药性。最后,我们回顾了当前的临床前研究,并讨论了开发基于 let-7 的替代策略的临床意义,作为潜在的癌症治疗药物,可通过不同的平台来靶向 CSCs,并在单独应用或与当前的化疗/放疗或分子靶向治疗联合应用时减少/克服治疗耐药性。通过专门针对 CSCs,这些策略有可能显著提高癌症治疗的疗效。